Navigation Links
Phytomedics Inc. To Present at BIO 2010 International Convention
Date:4/28/2010

JAMESBURG, N.J., April 28 /PRNewswire/ -- Phytomedics Inc., a clinical stage biopharmaceutical company developing a novel portfolio of drugs and consumer products solely derived from plant sources, today announced that Dr. Laurie Smaldone, MD, President and Chief Executive Officer, will deliver a corporate presentation at the BIO 2010 International Convention on Thursday, May 6th, at McCormick Place Convention Center in Chicago.

Dr. Smaldone's presentation will take place at 9:30 a.m. CDT in Presentation Room D, as part of the 2010 BIO Business Forum.

Her presentation will provide a corporate overview and highlight the clinical progress of the company's lead drug candidate, PMI-001, a novel, oral, disease-modifying, non-steroidal, natural product alternative to injectable biologicals in patients with RA.

Three U.S. based, FDA-approved clinical trials, have confirmed biological like efficacy of this botanical drug candidate as a stand-alone therapy in reducing signs and symptoms of RA at all American College of Rheumatology (ACR) endpoints,  a rapid onset of action and, the ability to halt joint erosions and narrowing with an acceptable side effect profile.  Combined with the fact that this natural botanical drug product is delivered as an oral dosage form, and has no steroid like side effects, makes PMI-001 truly is a game changing therapeutic opportunity in RA, as well as in the wider AA space.

About Phytomedics Inc.

Phytomedics, Inc. is a clinical stage biopharmaceutical company with a novel portfolio of drugs and consumer products solely derived from plant sources. Through this proprietary technology platform, the Company has produced a broad pipeline of lead product candidates, several of which are in clinical development.  The company's lead candidate, PMI-001, is a novel, oral, disease modifying anti-rheumatic drug currently being developed as a natural pharmaceutical alternative in rheumatoid arthritis therapy. Founded by Professor Ilya Raskin, Ph.D., presently the company's Chief Scientific Officer, Phytomedics Inc. conducts most of its discovery activities at the Biotech Center of Rutgers University.


'/>"/>
SOURCE Phytomedics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
10. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
11. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)...  Sequent Medical, Inc. announced today that it has ... safety and effectiveness of the WEB™ Aneurysm Embolization System ... Prof Laurent Spelle , MD, Head of Neuroradiology ... and Principal Investigator of the CLARYS study, ... and Germany.  Although patients with ruptured aneurysms have ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... WILMINGTON, North Carolina , 12 februari ... Laboratories, Inc. (AAI/CML), een toonaangevende leverancier van ... farmaceutische en biotechnologische industrieën, kondigt vandaag een ... en mogelijkheden op haar locatie in ... in vraag heeft geleid tot meerdere recente ...
Breaking Medicine Technology:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Prater Eye Center becomes the first in the area to offer AngioPlex™ Optical ... signs of retinal disease, such as macular degeneration, diabetic retinopathy, and other vascular ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... Many individuals ... of protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved ... it once more, but without the high-carb repercussions. IsoPasta has 30 grams of ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, ... gift of a VeinViewer® Vision vein finder for the nursing school ... an IV and draw blood, combining technology with traditional technique. , “VeinViewer is ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... According ... hernia surgeries are beginning to account for a significant portion of hernia repairs throughout ... Towfigh of the Beverly Hills Hernia Center notes that this trend has not only ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted over 250 members of South Florida’s philanthropic community at its 10th ...
Breaking Medicine News(10 mins):